[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07575230":3,"trial-entities:NCT07575230":96,"trial-summary:NCT07575230":100},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":21,"study_type":22,"primary_purpose":23,"phases":24,"enrollment_info":26,"interventions":29,"primary_outcomes":41,"secondary_outcomes":46,"sex":57,"minimum_age":58,"maximum_age":59,"healthy_volunteers":15,"eligibility_criteria":60,"std_ages":69,"locations":72,"central_contacts":82,"overall_officials":83,"references":88,"see_also_links":95},"NCT07575230","025-413","Suzetrigine vs Norco-postoperative Mohs Pain","Non-Opioid Pain Management After Mohs Reconstruction: An Investigator-Initiated, Prospective, Randomized Clinical Trial of Suzetrigine vs Hydrocodone\u002FAcetaminophen","ENROLLING_BY_INVITATION","2027-12","2026-05","2026-05-11","2025-11-03","Baylor Research Institute","OTHER",false,"To compare suzetrigine versus hydrocodone\u002Facetaminophen for postoperative pain control following dermatologic surgery.","This study is a randomized, controlled trial that is evaluating the safety and efficacy of suzetrigine as a postoperative pain medication compared to the standard of care Hydrocodone\u002FAcetaminophen in patients undergoing Mohs micrographic surgery (MMS) who are at high-risk for postoperative pain and opioid use. The goal is to reduce opioid prescription use and give patients a non-opioid pain medication option for particularly painful surgeries. Patients will be randomized into one of two groups, one group will receive the interventional medication and the other the standard of care medication.",[19,20],"Cutaneous Tumors","Mohs Micrographic Surgery",[],"INTERVENTIONAL","TREATMENT",[25],"PHASE4",{"count":27,"type":28},75,"ESTIMATED",[30,36],{"type":31,"name":32,"description":33,"armGroupLabels":34},"DRUG","Norco 5Mg-325Mg Tablet","Standard of care drug",[35],"Standard of Care",{"type":31,"name":37,"description":38,"armGroupLabels":39},"Suzetrigine","Control Drug",[40],"Control",[42],{"measure":43,"description":44,"timeFrame":45},"Change in need for opioid medication for pain management after Mohs micrographic surgery","Change in mean visual analog scale (VAS; 0-10) pain scores at 24 and 48 hours after surgery with a minimal change in pain score of 1.0 points.","48hours post surgery",[47,50,53],{"measure":48,"description":49,"timeFrame":45},"Patient-reported adequacy of pain control","Assessment of pain control with use of medication following surgery.",{"measure":51,"description":52,"timeFrame":45},"Rescue pain management use","Changes in need to use rescue medication for pain management",{"measure":54,"description":55,"timeFrame":56},"Adverse Events","Evaluation of occurence of adverse events (irregular heart beat, abnormal blood pressure, change in consciousness, or need for urgent care or emergency room visit in the first 3 days after surgery).","3 days after surgery","ALL","18 Years","89 Years",{"inclusion":61,"exclusion":64,"raw_text":68},[62,63],"adults between the age of 18-89","individuals who have a cutaneous tumor treated by MMS",[65,66,67],"individuals younger than 18 and older than 89","individuals taking medications that interact with the CYP3A (Cytochrome P450 3A) pathway","individuals with liver disease","Inclusion Criteria:\n\n* adults between the age of 18-89\n* individuals who have a cutaneous tumor treated by MMS\n\nExclusion Criteria:\n\n* individuals younger than 18 and older than 89\n* individuals taking medications that interact with the CYP3A (Cytochrome P450 3A) pathway\n* individuals with liver disease",[70,71],"ADULT","OLDER_ADULT",[73],{"facility":74,"city":75,"state":76,"zip":77,"country":78,"geoPoint":79},"Baylor University Medical Center","Dallas","Texas","75246","United States",{"lat":80,"lon":81},32.78306,-96.80667,[],[84],{"name":85,"affiliation":86,"role":87},"Stan Tolkachjov, MD","Baylor Medical University Center","PRINCIPAL_INVESTIGATOR",[89,93],{"pmid":90,"type":91,"citation":92},"22959232","BACKGROUND","Ad Hoc Task Force; Connolly SM, Baker DR, Coldiron BM, Fazio MJ, Storrs PA, Vidimos AT, Zalla MJ, Brewer JD, Smith Begolka W; Ratings Panel; Berger TG, Bigby M, Bolognia JL, Brodland DG, Collins S, Cronin TA Jr, Dahl MV, Grant-Kels JM, Hanke CW, Hruza GJ, James WD, Lober CW, McBurney EI, Norton SA, Roenigk RK, Wheeland RG, Wisco OJ. AAD\u002FACMS\u002FASDSA\u002FASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol. 2012 Oct;67(4):531-50. doi: 10.1016\u002Fj.jaad.2012.06.009. Epub 2012 Sep 5.",{"type":91,"citation":94},"Phillips, Shay, et al.",[],{"nct_id":4,"conditions":97,"biomarkers":99},[98],"Skin Neoplasm",[],{"nct_id":4,"found":15,"summary":101,"prompt_version":101},null]